Drug Landscape ›
Atorvastatin A ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 9
Most-reported reactions
Bacterial Infection — 1 report (11.11%) Biliary Sepsis — 1 report (11.11%) Cholangitis — 1 report (11.11%) Cholecystitis — 1 report (11.11%) Cholelithiasis — 1 report (11.11%) Gallbladder Disorder — 1 report (11.11%) Ileus — 1 report (11.11%) Pancreatitis — 1 report (11.11%) Post Procedural Complication — 1 report (11.11%)
Source database →
Atorvastatin A in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Atorvastatin A approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Atorvastatin A in United States?
Hanmi Pharmaceutical Company Limited is the originator. The local marketing authorisation holder may differ — check the official source linked above.